
Dutch health technology firm Philips has partnered with US-based cardiac imaging firm Myocardial Solutions to advance artificial intelligence (AI)-enabled cardiac magnetic resonance (CMR) imaging.
The partnership aims to deliver advanced care to more people, ensuring equitable outcomes and improved access to healthcare worldwide.
It will help detect heart disease early in cancer survivors and patients undergoing treatment, addressing cardiotoxicity caused by cancer therapies, said the Dutch health technology firm.
By improving early detection, the partnership aims to boost survival rates and enhance the quality of life for those recovering from cancer treatment.
Philips and Myocardial Solutions have introduced advanced imaging technologies like Fast-SENC and MyoStrain to detect early signs of cardiotoxicity.
The tools allow clinicians to measure subtle changes in heart function across 48 segments, identifying potential heart failure in just 10 minutes with under five minutes of analysis time
This early detection helps protect patients undergoing cancer treatments by identifying regional dysfunction before it affects the entire heart, Philips said.
Philips MR business leader Ioannis Panagiotelis said: “By combining our innovative BlueSeal innovation and SmartSpeed technologies with Myocardial Solutions’ specialised expertise in cardiac care, we aim to redefine the standard of cardiac care, environmental responsibility, and accessibility.”
Philips SmartSpeed, integrated with AI-driven Compressed SENSE and Adaptive-CS-Net, boosts scan speed and accuracy, reducing exam times by up to 3x while maintaining high image quality.
It also supports 97% of clinical protocols for both 2D and 3D cardiac imaging.
SmartSpeed enables advanced imaging techniques like angiography and T1 mapping, enhancing diagnostic confidence in complex cases, shortening CMR exams and optimising patient comfort.
According to the Dutch medical technology company, these capabilities will allow clinicians to perform faster imaging with lowered exam times, improving patient care and workflow efficiency.
By incorporating AI reconstruction early in the MR signal, it maintains image quality, paving the way for precise diagnostics and advanced CMR applications.
Furthermore, Philips’ next-generation BlueSeal system with helium-free technology tackles environmental challenges by reducing helium dependency and lowering the carbon footprint, supporting global sustainability goals.
The medical technology company said the BlueSeal mobile MRI system brings hospital-quality imaging to rural clinics and underserved areas.
Recently, Philips agreed to divest its Emergency Care Business to Bridgefield Capital, an American investment firm specialised in private equity, for an undisclosed sum.